Certara is the leading drug development consultancy with solutions spanning the discovery, preclinical and clinical stages of drug development.
PRINCETON, NJ – October 3, 2017 – Certara today announced the launch of Phoenix 8.0. Phoenix is the most advanced, intuitive, and widely-used software for pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) modeling and simulation.
Read MorePhoenix 8.0 continues to set the gold standard in PK/PD software by delivering innovative features that streamline PK/PD analysis and outcomes, saving time, reducing errors, and providing regulatory agencies with more transparency into the analytical process.
Read MoreThe minimum and optimal recommended hardware requirements are shown in this document. Optimal hardware requirements are recommended for ideal application performance with
large datasets and projects.
With the swearing in of Dr. Scott Gottlieb as Commissioner of Food and Drugs in May, many have wondered as to the climate he will set for the US FDA. Certara’s mission and business thesis aligns with the FDA’s July 7 announcement regarding the steps it is taking to implement the 21st Century Cures Act. […]
Read MorePhoenix NLME in Phoenix 8 Beta features parallelization for almost all run modes and the ability to run on powerful remote compute platforms, reducing run times from days to minutes.
Read MoreCertara’s Compute Grid allows you to access up to 1,800 cores in the cloud with just one click, significantly accelerating model runs. Projects that took days can now be completed in hours or even minutes, affordably and without IT support.
Read MoreThe Phoenix IVIVC Toolkit provides enhanced tools for in vitro-in vivo correlation studies used by formulation and pharmaceutical scientists to improve the success of BE studies. The IVIVC Toolkit approach requires less assumptions, as compared to other methods, and helps the user define the correlation observed from real in vivo profiles as compared to the dissolution profiles.
Read MoreIn vitro-in vivo correlation (IVIVC) is an important, predictive mathematical tool in drug development, used to enhance product and process understanding with the ultimate goal of ensuring consistent performance throughout the product’s life cycle.
Read MoreThe Phoenix WinNonlin Validation Suite is a desktop application that provides objective evidence of Phoenix WinNonlin functionality and streamlines the validation process through the use of automated tests accessed through a graphical user interface and validation document templates.
Read MoreCertara has developed the SEND Workflow Template for your Phoenix application. The Send Workflow Template prepares non-compartmental analysis (NCA) data in the format required by the FDA and other regulatory agencies for electronic submission.
Read MorePhoenix NLME is the PK/PD modeling software that is user-friendly and easy-to-learn. Built from the ground up on the Phoenix workbench architecture, Phoenix NLME enables users to focus on modeling, and not on the tools or coding required to implement the modeling. The result is more time for analysis and strategic decision-making.
Read MorePRINCETON, NJ – Aug. 10, 2016 – Certara, the leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes, today announced the launch of Phoenix 7.0. Phoenix is the most advanced, intuitive, and widely-used software for pharmacokinetic (PK), pharmacodynamic (PD), and toxicokinetic (TK) modeling and simulation.
Read MorePhoenix WinNonlin is the industry standard for the analysis of pharmacokinetic and pharmacodynamics data. The integrated tools for data processing, non-compartmental analysis (NCA), PK/PD modeling, post-analysis statistics, table creation, and graphics create an all-in-one collaboration workbench for analysts, reviewers, medical writers, and quality assurance team members.
Read MoreWatch this webinar with Certara’s Dr. Nathan Teuscher to learn more about the amazing features and enhancements now available in Phoenix 7.0.
Read MoreIn this webinar, we introduced delay differential equations and demonstrated their relationship with traditional models such as transit compartment models, typical absorption models, and models for describing atypical absorption profiles.
Read MoreGlobal, Tier 1 pharmaceutical company engages Phoenix Technology Services to develop a new solution that streamlines designing early clinical studies based on pre-clinical data.
Read More